About Fulgent Genetics
Fulgent Genetics is a company based in Temple City (United States) founded in 2011 was acquired by Fulgent Pharma in November 2022. Fulgent Genetics has raised $64.25 million across 5 funding rounds from investors including Fulgent Pharma. The company has 1,310 employees as of December 31, 2024. Fulgent Genetics has completed 5 acquisitions, including BakoDx, CSI Laboratories and Fulgent Pharma. Fulgent Genetics operates in a competitive market with competitors including Strand Life Sciences, Invitae, Genome Medical, Myriad Genetics and AnchorDx, among others.
- Headquarter Temple City, United States
- Employees 1310 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Fulgent Genetics, Inc.
-
Annual Revenue
$283.47 M (USD)-1.99as on Dec 31, 2024
-
Net Profit
-$42.71 M (USD)74.55as on Dec 31, 2024
-
EBITDA
-$48.99 M (USD)-12.52as on Dec 31, 2024
-
Total Equity Funding
$64.25 M (USD)
in 5 rounds
-
Latest Funding Round
$27.16 M (USD), Series A
May 24, 2016
- Investors
-
Employee Count
1310
as on Dec 31, 2024
-
Investments & Acquisitions
BakoDx
& 4 more
-
Acquired by
Fulgent Pharma
(Nov 07, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Fulgent Genetics
Fulgent Genetics is a publicly listed company on the NASDAQ with ticker symbol FLGT in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Fulgent Genetics
Unlock access to complete
Sales and Marketing
17 people
Leadership Team
12 people
Finance and Accounting
7 people
Software Development Team
5 people
Legal and Compliance
2 people
Operations Team
2 people
General Team
1 people
Human Resources and Administration
1 people
Unlock access to complete
Funding Insights of Fulgent Genetics
Fulgent Genetics has successfully raised a total of $64.25M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $27.16 million completed in May 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Fulgent Genetics
Fulgent Genetics has secured backing from 1 investor. Prominent investors backing the company include Fulgent Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Drugs for cancer treatment are developed using nanoencapsulation technology.
|
Locked | Locked | Locked |
Investor details for Fulgent Genetics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Fulgent Genetics
Fulgent Genetics has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include BakoDx, CSI Laboratories and Fulgent Pharma.
Investment portfolio details for Fulgent Genetics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Standalone pathology lab services are offered in the United States.
|
Locked | Locked | 2018 | Locked | |
|
Pathology testing services are offered by a standalone laboratory.
|
Locked | Locked | 2011 | Locked | |
|
Drugs for cancer treatment are developed using nanoencapsulation technology.
|
Locked | Locked | 2011 | Locked |
Complete acquisition details for Fulgent Genetics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Fulgent Genetics
Detailed financials for Fulgent Genetics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Fulgent Genetics Comparisons
Peer comparison for Fulgent Genetics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Fulgent Genetics
Fulgent Genetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Strand Life Sciences, Invitae, Genome Medical, Myriad Genetics and AnchorDx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Home-based genetic tests for detecting diseases are provided to individuals.
|
|
| Locked | Locked | Locked |
Genomic testing services are provided clinically and directly to consumers.
|
|
| Locked | Locked | Locked |
Molecular diagnostics and personalized medicine for cancer are developed.
|
|
| Locked | Locked | Locked |
High-throughput gene sequencing platform is developed for clinical diagnostics.
|
Detailed competitors of Fulgent Genetics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Fulgent Genetics
Complete news archive for Fulgent Genetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fulgent Genetics
Fulgent Genetics was founded in 2011 and raised its 1st funding round 4 years after it was founded.
Fulgent Genetics is headquartered in Temple City, United States. It is registered at Temple City, California, United States.
Ming Hsieh is the current CEO of Fulgent Genetics.
Fulgent Genetics is a funded company, having raised a total of $64.25M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Fulgent Genetics is 1,310.
Annual revenue of Fulgent Genetics is $283.47M as on Dec 31, 2024.
Fulgent Genetics was founded in 2011 and is headquartered in Temple City, United States. Genetic testing services are provided in the healthcare sector, focusing on carrier screening for cardiovascular diseases, epilepsy, and cancer. Next-generation sequencing technology is utilized for rare diseases, whole-genome sequencing, copy number variation analysis, and mitochondrial sequencing to support clinical diagnostics.
Fulgent Genetics's top competitors include Strand Life Sciences, Centogene and Myriad Genetics.
Yes, Fulgent Genetics is publicly traded on NASDAQ under the ticker symbol FLGT.
Fulgent Genetics has made 5 acquisitions, including BakoDx, CSI Laboratories, and Fulgent Pharma.
Fulgent Genetics has 1 investor. Key investors include Fulgent Pharma.
The ticker symbol of Fulgent Genetics is FLGT on NASDAQ.